Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RCFGO
ADC Name
DAB4-DuoDM
Synonyms
DAB4 DuoDM
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
4.2
Antibody Name
DAB4
  Antibody Info 
Antigen Name
Lupus La protein (SSB)
  Antigen Info 
Payload Name
DEAEA duocarmycin
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG4-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 71.4
%
A-549 cells
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 71.40% (Day 8) Positive La/SSB expression (La/SSB +++/++)
Method Description
A549 tumor-bearing mice were treated intraperitoneally with 150 mg/kg gemcitabine and 3 mg/kg cisplatin on Day 1. The day after chemotherapy, mice were treated with an intravenous injection of ADC.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
References
Ref 1 APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo. Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.